HUYA Bioscience International, a leader in accelerating the global development of China’s pharmaceutical innovations, announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD). This partnership will focus on advancing the worldwide potential of innovations from bio-pharmaceutical companies located in Changzhou that could meet critical global pharmaceutical pipeline needs.

HUYA is one of the first companies to have recognized China’s potential to help meet the global need for new preclinical and clinical stage compounds. The company is focused on speeding the development and value creation for China sourced novel biopharmaceutical compounds in world-wide markets. HUYA has established a series of collaborations with leading universities and research institutes throughout China and has pioneered in-licensing of both preclinical and clinical stage compounds from the country.

The CZCBD, an institutional unit fully funded and supervised by the Changzhou Science & Technology Bureau, is the first biotechnology development center to operate under local government supervision. It is dedicated to establishing a comprehensive bio-pharmaceutical innovation system and to transforming the output of the more than 800 biotechnology and pharmaceutical companies based within Changzhou. These companies and enterprises represent fields including biopharmaceuticals, chemical drugs, medical devices, equipment and consumables, traditional Chinese medicine, industrial biology, bioagriculture, bioenvironmental protection and bioenergy.

This partnership enables HUYA and CZCBD to collaborate on promoting new drug development in China and worldwide. Local biopharmaceutical companies serviced by CZCBD will be able to leverage HUYA’s global biopharmaceutical knowledge and network, and consult with HUYA’s team of experts in drug development and commercialization. In turn, HUYA will have the right of priority review to evaluate certain research and development projects of local companies supported by CZCBD, providing advice and consultation as needed.

“HUYA is delighted to work with the prestigious Changzhou Center for Biotech Development in a partnership that aims to advance the development and commercialization of innovative pharmaceutical compounds and biomarkers,” said Clement Gingras, HUYA’s chief technology officer and chief operating officer Asia. “We are very excited about this partnership and look forward to fruitful collaborations in the years to come.”

Xin Zhou, Director of the Changzhou Center for Biotech Development, also expressed optimism about this collaboration. “This partnership connects Changzhou’s resources in biomedical science and technology with HUYA’s experience and resources in international new drug development, broadens access to worldwide markets for Changzhou’s biomedical companies, and accelerates the global reach of innovative pharmaceutical technologies and products from Changzhou.”

Changzhou Center for Biotechnology Development (CZCBD) is an institutional unit fully funded and supervised by the Changzhou Science & Technology Bureau. The center was renamed from the Changzhou Institute of Ecological Technology Application and approved by Changzhou City on January 11, 2013. The main responsibilities of CZCBD are participating in the formulation of policy plans for S&T projects, integrating resources of biotech and related industries, facilitating biotech innovation and development, and providing services for agricultural biotech innovation and agricultural modernization.